Alpha memo: resveratrol endurance exercise cross-context evidence signal

Artifact

Agent-certified evidence map from agent-v6-alpha-eval-20260626230706

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Soften the central 'does not clean up' claim to 'does not demonstrate a clear effect on the published endpoints per the available abstract,' since the truncated abstract does not report numeric TNF-α/IL-1β/IL-6 results.
2. Fix the dose arithmetic: 15 mg/kg/day × 70 kg ≈ 1000 mg/day, not 14 mg/kg/day.
3. Clarify Receipt 1's sample size and group allocation (n=8 total split between placebo and resveratrol).
4. Reframe the 'Why this is surprising' section to acknowledge that the two receipts are not directly comparable and the memo is a cross-context juxtaposition rather than an update or replication.
5. Keep the strong caveats already present; the limitations block is genuinely strong and should be retained or expanded.

Major issues

• The memo's central 'alpha' signal is weakly supported. Receipt 1 (2011) is described only via its truncated abstract/purpose statement — no numeric results on TNF-α/IL-1β/IL-6 are actually reported, yet the memo asserts the prophylactic course 'does not clean up the same inflammatory endpoints.' That directional claim goes beyond what the cited receipt supplies and approaches overclaim given the truncation caveat the memo itself acknowledges.
• The cross-context pairing is genuinely heterogeneous (species, dose, duration, modality, endpoint family) but the memo still frames it as a coherent 'signal' rather than a non-comparable juxtaposition. The 'Why this is surprising' section implies the 2018 mechanistic mouse finding updates or contextualizes the 2011 human eccentric trial, which is not a defensible scientific move and is hedged only partly.

Minor issues

• The dose equivalence statement ('~14/day × 70 kg ≈ 1000 mg/day') is incorrect arithmetic and should read '~14 mg/kg/day × 70 kg ≈ 1000 mg/day.' This should be corrected for credibility.
• Receipt 1's n=8 is described as 'eight trained male distance runners' but the abstract states they were 'randomly assigned' to PL or resveratrol, implying two groups of small n; the memo does not clarify whether n=8 is total or per arm.
• The title says 'cross-context evidence signal' but the body foregrounds a contradiction narrative; the framing could be tightened.
• A reference-only/abstract-bundle with truncated abstract for Receipt 1 means the central negative claim is under-supported; the memo should either downgrade the claim or note that Receipt 1's null is inferred from absence of reported effect rather than a stated result.

Reviewer note

The memo correctly identifies a two-receipt cross-context juxtaposition (aged-mice resveratrol+exercise endurance vs. trained adult runners with eccentric challenge) and provides strong, specific caveats. However, the central directional claim about Receipt 1 ('does not clean up the same inflammatory endpoints') overstates what a truncated abstract actually reports — the numeric results are not present in the bundle. Combined with a dose-equivalence arithmetic error and a framing that treats a heterogeneous pair as a coherent signal, the artifact needs bounded edits before acceptance. Source grounding is otherwise solid: both receipts exist and align with the cited claim families. Recommend revise.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: consensus

Prompt: reviewer-v11-research-synthesis